1. Home
  2. KLTO vs PPBT Comparison

KLTO vs PPBT Comparison

Compare KLTO & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KLTO
  • PPBT
  • Stock Information
  • Founded
  • KLTO 2019
  • PPBT 2010
  • Country
  • KLTO United States
  • PPBT Israel
  • Employees
  • KLTO N/A
  • PPBT N/A
  • Industry
  • KLTO
  • PPBT Biotechnology: Pharmaceutical Preparations
  • Sector
  • KLTO
  • PPBT Health Care
  • Exchange
  • KLTO NYSE
  • PPBT Nasdaq
  • Market Cap
  • KLTO 8.3M
  • PPBT 6.7M
  • IPO Year
  • KLTO N/A
  • PPBT N/A
  • Fundamental
  • Price
  • KLTO $0.48
  • PPBT $3.61
  • Analyst Decision
  • KLTO
  • PPBT Strong Buy
  • Analyst Count
  • KLTO 0
  • PPBT 2
  • Target Price
  • KLTO N/A
  • PPBT $126.50
  • AVG Volume (30 Days)
  • KLTO 992.6K
  • PPBT 2.7M
  • Earning Date
  • KLTO 02-15-2025
  • PPBT 11-15-2024
  • Dividend Yield
  • KLTO N/A
  • PPBT N/A
  • EPS Growth
  • KLTO N/A
  • PPBT N/A
  • EPS
  • KLTO N/A
  • PPBT N/A
  • Revenue
  • KLTO N/A
  • PPBT N/A
  • Revenue This Year
  • KLTO N/A
  • PPBT N/A
  • Revenue Next Year
  • KLTO N/A
  • PPBT N/A
  • P/E Ratio
  • KLTO N/A
  • PPBT N/A
  • Revenue Growth
  • KLTO N/A
  • PPBT N/A
  • 52 Week Low
  • KLTO $0.26
  • PPBT $2.00
  • 52 Week High
  • KLTO $13.10
  • PPBT $20.60
  • Technical
  • Relative Strength Index (RSI)
  • KLTO N/A
  • PPBT 47.73
  • Support Level
  • KLTO N/A
  • PPBT $3.56
  • Resistance Level
  • KLTO N/A
  • PPBT $4.22
  • Average True Range (ATR)
  • KLTO 0.00
  • PPBT 1.42
  • MACD
  • KLTO 0.00
  • PPBT -0.07
  • Stochastic Oscillator
  • KLTO 0.00
  • PPBT 3.36

About KLTO KLOTHO NEUROSCIENCES INC

Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.

Share on Social Networks: